Exelixis

NASDAQ: EXEL
$16.52
-$0.13 (-0.8%)
Closing price April 3, 2020
The top analyst upgrades, downgrades and initiations seen on Monday included Chipotle Mexican Grill, Delphi Technologies, Dollar General, Facebook, Ingersoll-Rand, Nike, Okta and Quest Diagnostics.
Lee Jackson
The top analyst upgrades, downgrades and initiations seen on Friday included Biogen, Broadcom, Citigroup, Equifax, Fitbit, Intel, Kraft Heinz, Merck, Roku, Under Armour, United Technologies and...
Jon C. Ogg
The biotech team at SunTrust feel that it would not be a major surprise to see these six top companies post quarterly results that beat top-line Wall Street expectations.
Lee Jackson
Sears, Weyerhaeuser, Laredo Petroleum, and Exelixis were among the stocks posting new 52-week lows Monday.
Paul Ausick
Exelixis shares dipped on Monday after the company announced that it has initiated a late-stage trial in patients with radioiodine-refractory differentiated thyroid cancer (DTC).
Chris Lange
JD.com, Turquoise Hills, Exelixis, and Floor & Decor Holdings all posted new 52-week lows Monday.
Paul Ausick
Invesco, Tal Education, Chemours, and Exelixis all posted new 52-week lows on Thursday.
Paul Ausick
SeaChange, Sears, Exelixis, and Adamis Pharma all posted new 52-week lows Tuesday.
Paul Ausick
Lannett Co., Scorpio Tankers, Mobile Telesystems, and Exelixis all posted new 52-week lows Monday.
Paul Ausick
These four top Suntrust biotech picks for 2018 all have the potential for big upside moves if they do indeed exceed first-quarter expectations.
Lee Jackson
The include Albermarle, Best Buy, Chipotle Mexican Grill, Exact Sciences, Fitbit, Itron, NuVasive, Palo Alto Networks and Stryker.
Jon C. Ogg
Shares of Exelixis slipped on Wednesday after the company reported results from its late-stage trial of cabozantinib for advanced hepatocellular carcinoma.
Chris Lange
Exelixis saw its shares make a handy gain on Wednesday after the company received the nod from the FDA for Cabometyx tablets.
Chris Lange
With tax reform having cleared the Senate and going back to the House, investors were looking for a higher stock market open on Wednesday.
Jon C. Ogg
Exelixis kicked off the week with a couple updates that are already having a big impact on the stock. These updates came in the form of a key FDA approval.
Chris Lange